PreludeDx Announces New Response Type Biosignature Data at the 37th Annual Miami Breast Cancer Conference
New Response Type Biosignature Identifies Women at Elevated Risk of Recurrence after Surgery and Radiation Therapy for DCIS
DCISionRT integration into decision-making changed treatment recommendations in 45% of women with DCIS
Prospective Trial near... Diagnostics, Oncology PreludeDx, DCISionRT, ductal carcinoma, breast cancer, DCIS
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Conferences | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Pharmaceuticals | Radiation Therapy | Women